Industry News
Pharmaceutical Industry News
Monday, CSL broke ground on an…
Monday, CSL broke ground on an expansion at its Kankakee, Illinois, facility, a move set to substantially bolster the company’s production capacity for plasma-derived therapy.
About five months after U.S….
About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism” during a White House press conference, the
After nearly nine years as GSK’s…
After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million).
The FDA’s newest draft guidance…
The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug development by removing certain testing requirements for the cheaper biologic drugs.
With sales booming at Eli Lilly,…
With sales booming at Eli Lilly, the Indianapolis company has compensated CEO David Ricks with a $36.7 million pay package in 2025, which is up from $29.2 million in 2024.
Spruce Biosciences has named Dale…
Spruce Biosciences has named Dale Hooks as chief commercial officer, securing a leader with experience launching 21 products as the company heads toward a filing for its first FDA approval.
The agreement marks the end of a…
The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its telehealth platform.
With a new FDA nod in hand for…
With a new FDA nod in hand for Sotyktu as a treatment for adults with active psoriatic arthritis, Bristol Myers Squibb can reach more patients with the oral TYK2 inhibitor.
The sketch show’s latest pharma…
The sketch show’s latest pharma ad spoof arrived during this past weekend’s episode hosted by actor Ryan Gosling, who appears in the Otezla send-up as a patient now able to shed his long sleeves after
Issues at a former Catalent plant…
Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line
After an independent data…
After an independent data monitoring committee raised safety flags in a clinical trial, Ipsen is shutting down the cancer med Tazverik, which it picked up through its acquisition of Epizyme less than four years ago.
Under the deal with Lone Star…
Under the deal with Lone Star Funds, Lonza maintains a 40% stake in its capsules and health ingredients business while receiving 1.7 billion Swiss francs ($2.2 billion) upfront.
Sen. Ron Wyden of Oregon is going…
Sen. Ron Wyden of Oregon is going straight to drugmakers in search of details on their "most favored nation" pricing deals with Donald Trump.
Sanofi has agreed to sell its…
Sanofi has agreed to sell its Medley generics unit in Brazil to leading local drugmaker EMS, according to an announcement from international law firm Mayer Brown. An EMS exec said the deal is valued at
Almost all of last month’s top…
Almost all of last month’s top 10 pharma TV ad spenders took advantage of February’s two major sporting events to get the word out about their meds.
The three-pronged plan to…
The three-pronged plan to strengthen domestic drug supply will be supported by an investment of 24 billion new Taiwan dollars ($755 million), President Lai Ching-te said.
Less than two weeks after Pfizer…
Less than two weeks after Pfizer struck a deal with Sciwind Biosciences to gain commercial rights to a GLP-1 drug, China's National Medical Products Administration (NMPA) has approved the treatment for patients with obesity.
Servier on Friday unveiled a deal…
Servier on Friday unveiled a deal to acquire Day One Biopharmaceuticals—a commercial-stage company developing targeted therapies for pediatric cancers and other diseases—for $21.50 per share in cash. The total value of the deal, which is
Kyowa Kirin has decided to…
Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. Sanofi is committing up to $1.5 billion for global rights to Sino Biopharm's first-in-class JAK/ROCK inhibitor.
La mayoría de los pacientes mantendrían su peso con menos dosis de medicamentos GLP-1
En una investigación reciente, un pequeño grupo de pacientes recibió las inyecciones con menos frecuencia, pero aun así mantuvo la pérdida de peso y los beneficios para la salud.